PCIF1 and colorectal carcinoma: PCIF1, the writer of m6Am, has been shown to modulate anti-PD-1 therapy in CRC (35).Thus, the inhibitors/activators of m6A/m6Am regulators have shown potential clinical implications as adjuvant therapies to improve the response to anti-PD-1 therapy or reduce resistance.